fashion -WSS

fashion

author：comprehensive 2025-09-30 00:01:00 - browse：35

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Cord blood banking comes at a high cost to babies

hotspot

WSS

See how much Covid

Vertigo drug brings hope for rare neuron disorder, Niemann

Apple Vision Pro: A first look at health apps on the new VR headset

New Ultima Genomics DNA sequencer can read genome for $100

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Ionis drug prevents swelling attacks due to hereditary angioedema

hotspot

fashion

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Change Healthcare can notify patients about the breach, HHS says

In Memoriam: Notable people who died in 2023

How to increase colonoscopy rates? Looks like an AI can help

Guidelines to prevent youth baseball injuries need more muscle

A $475,000 price tag for a new cancer drug: crazy or meh?

The high cost of giving birth even with insurance

Woodcock on FDA’s accelerated approval and her next chapter

Heart attack and stroke risk calculators need revising

HIV drugs protect against transmission, even in unprotected sex

knowledge

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Commercial surrogacy can be ethical, despite pope’s claims

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Wikipedia

hotspot

Wikipedia

leisure time